详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China.

100| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China [2]Neurological Laboratory of Hebei Province, Shijiazhuang, 050000, Hebei, China [3]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China [4]Department of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China [5]The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China [6]Beijing Tiantan Hospital, Capital Medical University, Beijing, China [7]West China Hospital, Sichuan University, Chengdu, China [8]Xuanwu Hospital, Capital Medical University, Beijing, China [9]The First Affiliated Hospital of Shanxi Medical University, Taiyuan, China [10]The First Hospital of Jilin University, Changchun, China [11]Xiangya Hospital, Central South University, Changsha, China

出处：

DOI：

ISSN：

关键词： Multiple sclerosis Disease burden Health economics Disability-adjusted life years

摘要：

To assess the disease burden and health economics of inpatients with multiple sclerosis (MS) in China by evaluating the direct, indirect, and intangible costs.A total of 863 patients were included for a cross-sectional retrospective study in 50 centers. The direct economic burden was measured by the cost of hospitalization and out-of-hospital application drugs, and the indirect economic burden was measured by the human capital method. The disability-adjusted life year (DALY) was used to express the intangible economic burden. Cost-utility analysis (CUA) using DALYs as indicators of health benefits was performed by calculating the incremental cost-utility ratio.The mean direct economic burden/year, daily medication expenses/year, DALY, indirect economic burden, and indirect economic burden/year were 27,655.57 Yuan, 17,944.97 Yuan, 10.89 Yuan, 512,041.7 Yuan, and 11,299.85 Yuan, respectively. For the study period of two years, the direct economic burden, daily medication expense, and indirect economic burden were 48.6%, 31.5%, and 19.85% of the total economic burden, respectively. Disease burden and the number of episodes of remission were not statistically significant (p>0.001). The direct economic burden and total economic burden of the disease-modifying therapy (DMT) group were higher than those of the non-DMT group, but DALYs had no statistical significance (p>0.001). CUA showed that inpatients with MS in the DMT group received a DALY every time compared with the non-DMT group.The DALY losses are concentrated in young and middle-aged Chinese people. In this two-year study, CUA prompted the application of DMT drugs to increase the economic burden and DALYs. However, follow-up time is still short, and further follow-up observation is required.Copyright © 2022. Published by Elsevier B.V.

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 3 区医学

小类 | 4 区临床神经病学

最新[2023]版：

大类 | 3 区医学

小类 | 4 区临床神经病学

JCR分区：

出版当年[2020]版：

Q2 CLINICAL NEUROLOGY

最新[2023]版：

Q2 CLINICAL NEUROLOGY

影响因子： 2.9 最新[2023版] 3.2 最新五年平均 4.339 出版当年[2020版] 4.292 出版当年五年平均 2.889 出版前一年[2019版] 4.808 出版后一年[2021版]

第一作者：

第一作者机构： [1]Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China [2]Neurological Laboratory of Hebei Province, Shijiazhuang, 050000, Hebei, China

通讯作者：

通讯机构： [1]Department of Neurology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, Hebei, China [3]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China [*1]215 Heping West Road, Shijiazhuang City, 050000, Hebei Province [*2]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China- 100032.

推荐引用方式(GB/T 7714)：

APA：

MLA：

A multicenter study to evaluate the disease burden and health economics of inpatients with multiple sclerosis in China.

文献详情

相关文献